Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL protocol

por Iturbe-Hernandez, Teodoro, García de Guadiana Romualdo, Luis, Gil Ortega, Ignacio, Martínez Francés, Antonio, Meca Birlanga, Olga, Cerezo-Manchado, Juan José
Publicado 2020

Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL protocol

por Cerezo-Manchado, Juan José, Meca Birlanga, Olga, García de Guadiana Romualdo, Luis, Gil-Ortega, Ignacio, Martínez Francés, Antonio, Iturbe-Hernandez, Teodoro
Publicado 2022

Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry

por Cerezo Manchado, Juan José, Iturbe Hernández, Teodoro, Martínez Pacheco, María del Carmen, Gil Ortega, Ignacio, Campoy, Desirée, Canals Pernas, Tania, Martinez Serra, Laia, Flores Aparco, Katia Jessica, Velasquez Escandon, Cesar Andres, García de Guadiana-Romualdo, Luis, Martinez Frances, Antonio, Olivera, Pavel
Publicado 2023

The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality

por Cerezo Manchado, Juan Jose, Olivera, Pável E, Lopez Abellan, María Dolores, Campoy Castaño, Desiree, Velasquez, César A, Rodriguez Rojas, Carlos, Ramos Arenas, Veronica, Flores, Katia, Cárdenas Gámez, Rubén, García de Guadiana Romualdo, Luis, Iturbe Hernandez, Teodoro, Sierra, Jorge, Salinas, Ramón
Publicado 2020